Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TScan Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for TScan Therapeutics, Inc.

TCRX

TScan Therapeutics, Inc.

About TScan Therapeutics, Inc.

TScan Therapeutics develops T cell receptor (TCR)-engineered T cell therapies targeting cancer. Its platform identifies clinically relevant TCRs from patients with exceptional responses, enabling personalized and multiplexed treatments for hematologic malignancies and solid tumors. The company focuses on creating scalable manufacturing processes, expanding its TCR bank, and advancing clinical trials to deliver innovative immunotherapies that address tumor heterogeneity and resistance.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TScan Therapeutics, Inc.

1
1
TScan Therapeutics, Inc. TScan Therapeutics Reports Q1 2026 Financial Results with Revenue Decline and Improved Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
TScan Therapeutics, Inc. TScan Therapeutics Reports $129.8M Net Loss and Strategic Shift in Clinical Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
TScan Therapeutics, Inc. TScan Therapeutics Reports Q3 2025 Revenue Growth but Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TScan Therapeutics, Inc. TScan Therapeutics Reports Revenue Growth but Increased Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TScan Therapeutics, Inc. TScan Therapeutics Reports $2.2 Million Revenue in Q1 2025, Net Loss of $34.1 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TScan Therapeutics, Inc. TScan Therapeutics Reports $127.5 Million Net Loss for 2024, Revenue Drops to $2.8 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TScan Therapeutics, Inc. TScan Therapeutics Reports Decline in Collaboration Revenue, Increased Operating Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments